Relationship between 5‐fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy

• Published in: British journal of clinical pharmacology Vol. 64; no. 5; pp. 613 - 621
• Main Authors: Beneton, Maud, Chapet, Sophie, Blasco, Hélène, Giraudeau, Bruno, Boisdron‐Celle, Michèle, Deporte‐Fety, Régine, Denis, Fabrice, Narcisso, Bérangère, Calais, Gilles, Le Guellec, Chantal
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.11.2007; Blackwell Science; Blackwell Science Inc
• Subjects: 5‐fluorouracil; Antineoplastic agents; Biological and medical sciences; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - radiotherapy; Combined treatments (chemotherapy of immunotherapy associated with an other treatment); Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; drug monitoring; Female; Fluorouracil - administration & dosage; Fluorouracil - adverse effects; Fluorouracil - pharmacokinetics; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - radiotherapy; Humans; Immunosuppressive Agents - administration & dosage; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - pharmacokinetics; Male; Medical sciences; pharmacokinetics; Pharmacokinetics and Pharmacodynamics; Pharmacology. Drug treatments; Pilot Projects; Treatment Outcome; Antineoplastic agent; Prognosis; Intravenous administration; Continuous; Toxicity; drug monitoring; Therapeutic drug monitoring; Activity concentration relation; ENT disease; Fluorouracil; Human; Enzyme; Fluoropyrimidine derivatives; Transferases; Enzyme inhibitor; Malignant tumor; Thymidylate synthase; Radiotherapy; 5-fluorouracil; Chemotherapy; Antimetabolic; Methyltransferases; Perfusion; Pyrimidine derivatives; Head and neck cancer; Combined treatment; Pharmacokinetics

What is already known about this subject • Dihydropyrimidine dehydrogenase (DPD) deficiency is currently evaluated as a means of identifying patients with a risk of toxicity during 5‐fluorouracil (5‐FU) treatment. • Therapeutic drug monitoring (TDM) is a complementary tool already shown to be useful...